Advertisement

Topics

Latest Collaborations in biotechnology NewsRSS

06:45 EDT 29th June 2017 | BioPortfolio

Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement

Bioquark, Inc.and Lakmus LLC, announce a multi-disciplinary research collaboration to study age-reversal / longevity enhancing bio-pharmaceutical development with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences and the Pavlov Institute of Physiology of the Russian Academy of Sciences. Phila, PA (PRWEB) June 29, 2017 Bioquark, Inc., (http://www.bioquark.com) a life ...

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) (LON/STO/NYSE: AZN) today announce that they have initiated a global pivotal Phase III, open-label, randomized multi-center registration study of the highly selective inhibitor of c-MET receptor tyrosine kinase, savolitinib, in c-MET-driven papillary ...

VoltageDependent Calcium Channel Blockers Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, VoltageDependent Calcium Channel BlockersPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the VoltageDependent Calcium Channel Blockers. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, Phase III and Preregistration....

Bioenergy Life Science, Inc. Posts Record Growth in First Six Months After Joining Top Chinese Biotech Company

MINNEAPOLIS, May 30, 2012 /PRNewswire/ -- Revenue for the first six months of Bioenergy Life Science, Inc. has shown significant growth since being acquired by China's top biotechnology company, Chengzhi Life Sciences Company Ltd.  Under the terms of the agreement, Bioenergy Life Science continues to provide its highest quality patented Bioenergy Ribose® to its customers. "We ...

Lilly's Commitment to Global Innovation Reinforced with Opening of New Diabetes-Focused Research and Development Center in Shanghai

SHANGHAI, May 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has officially opened the Lilly China Research and Development Center (LCRDC), a key component of its significant and sustainable commitment to China. The goal of the LCRDC is to discover innovative diabetes medicines with novel mechanisms of action that can be tailored specifically for the Chinese pop...

Phosphodiesterase PDE Inhibitors Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, Phosphodiesterase PDE InhibitorsPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Phosphodiesterase PDE Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the...

RON Recepteur d'origine Nantais Inhibitors Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, RON Recepteur d'origine Nantais InhibitorsPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the RON Recepteur d'origine Nantais Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, Phase III and Preregistratio...

Tumor Necrosis Factor Receptor TNFR Antagonists Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, Tumor Necrosis Factor Receptor TNFR AntagonistsPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Tumor Necrosis Factor Receptor TNFR Antagonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, Phase III and Prer...

Receptor For Advanced Glycation End Product RAGE Inhibitors Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, Receptor For Advanced Glycation End Product RAGE InhibitorsPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Receptor For Advanced Glycation End Product RAGE Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phas...

Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases

LAUSANNE, Switzerland and SUZHOU, China, June 18, 2012 /PRNewswire/ -- Debiopharm Group™ (Debiopharm), a global biopharmaceutical development group that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc. (Ascepion), a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule dr...

TRAIL Receptor 1 TRAILR1 or Death Receptor 4 or DR4 Agonists Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, TRAIL Receptor 1 TRAILR1 or Death Receptor 4 or DR4 AgonistsPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the TRAIL Receptor 1 TRAILR1 or Death Receptor 4 or DR4 Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Ph...

Heptares and PeptiDream Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Therapeutics in Inflammatory Disease

LONDON and TOKYO, June 29, 2017 /PRNewswire/ -- Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), and PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream"; TOKYO: 4587), have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed...

Physicians Realty Trust Announces Pricing of Public Offering of 20,000,000 Common Shares

Physicians Realty Trust (NYSE:DOC) (the “Company”), a self-managed healthcare real estate company, announced today the pricing of a public offering of 20,000,000 common shares of beneficial interest at a public offering price per share of $20.40, for net proceeds of approximately $390.98 million after deducting the underwriting discount and commissions...

TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine

TAIPEI, Taiwan, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhejiang Medicine Company, Limited ("ZMC") today announced that they have signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau).  Nemonoxacin is a novel broad-spectrum non-fluorinated ...

SerotoninNorepinephrineDopamine Reuptake InhibitorsSNDRI Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, SerotoninNorepinephrineDopamine Reuptake InhibitorsSNDRIPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the SerotoninNorepinephrineDopamine Reuptake InhibitorsSNDRI. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, ...

Thioredoxin Reductase Inhibitors Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, Thioredoxin Reductase InhibitorsPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Thioredoxin Reductase Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the...

Genomic Vision Extends its Patent Portfolio With the Genomic Morse Code

PARIS, July 3, 2012 /PRNewswire/ -- Genomic Vision, a leading biotechnology company specializing in developing genetic diagnostic tests using DNA molecular combing, is announcing the extension of its intellectual property portfolio, with the granting in several countries of a patent on an innovative method of structural and visual analysis of the genome, called Genomic Morse Code (GMC).  &#...

ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment

LONDON, July 18, 2012 /PRNewswire/ -- ViiV Healthcare today announced a broad range of groundbreaking initiatives as part of its ongoing commitment to address the gaps in care and treatment of paediatric HIV. These efforts are part of the company's Paediatric Innovation Seed Fund. They include a public-private partnership with CHAI and Mylan Laboratories Limited, a subsidiary of US-based Mylan Inc...

Kindred Healthcare, Billings Clinic and St. Vincent Healthcare Announce Plans for Rehabilitation Hospital

Partnership will construct and operate a 34-bed hospital in Billings, Montana Kindred Healthcare, Inc. (“Kindred”) (NYSE:KND), Billings Clinic and St. Vincent Healthcare today announced the signing of a definitive agreement to create a partnership to construct and operate a 34-bed inpatient rehabilitation hospital in Billings, Montana. This S...

Phosphoinositide 3Kinase Alpha PI3K Alpha Inhibitors Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, Phosphoinositide 3Kinase Alpha PI3K Alpha InhibitorsPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Phosphoinositide 3Kinase Alpha PI3K Alpha Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, Phase II...

Walgreens and LabCorp Collaborate to Bring Patient Service Centers for Laboratory Testing to Select Walgreens Stores

“LabCorp at Walgreens” Sites Will Provide Specimen Collection Services for LabCorp Testing Seven Service Centers Planned to Open at Walgreens Stores in 2017 Walgreens and LabCorp® (NYSE: LH) today announced a collaboration through which LabCorp will develop and operate patient service centers within select Walgreens stores. The centers, w...

Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Cad Software

SHELTON, Connecticut, July 30, 2012 /PRNewswire/ -- International medical technology company, Sectra  (NASDAQ OMX Stockholm: SECT B), announces an agreement with Merge Healthcare to distribute its CADstream[TM] Software, fully integrated with Sectra Breast Imaging PACS.      (Logo: http://photos.prnewswire.com/prnh/20120601/537255 ) This strategic agreem...

Physicians Realty Trust Announces Public Offering of 20,000,000 Common Shares

Physicians Realty Trust (NYSE:DOC) (the “Company”), a self-managed healthcare real estate company, announced today that it has commenced a public offering of 20,000,000 common shares of beneficial interest. The Company also plans to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares. All of the common shares in ...

Life Sciences Industry Veteran Joins Huron to Expand Global Business

John Westwood brings 25 years of leadership and industry experience Global professional services firm Huron (NASDAQ: HURN) today announced that life sciences and strategy thought leader John Westwood has joined the company as managing director and global head of Huron’s life sciences practice. He will lead the team that partners with pharmaceutical, ...

Src Tyrosine Kinase Inhibitors Pipeline Insights, 2017 [Report Updated: 30052017] Prices from USD $1063

DelveInsight's, Src Tyrosine Kinase InhibitorsPipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Src Tyrosine Kinase Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the pro...

Quick Search
Advertisement
 

review and buy Collaborations in biotechnology market research data and corporate reports here